Romidepsin (FK228, Depsipeptide)

製品コードS3020 別名:FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide)化学構造

分子量(MW):540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 26062.00
JPY 79182.00
JPY 115702.00

カスタマーフィードバック(4)

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
特性 More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
ターゲット
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外試験

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 M4HXTGNmdGxiVnnhZoltcXS7IFHzd4F6 MXWyMlUuOTVibl2= NFTxflY4OiCq NF3QZm5qdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NX3aSm1MOjV5OUC5NFc>
U2932  NUfI[G5JS2WubDDWbYFjcWyrdImgRZN{[Xl? NGnPSpYzNjVvMUWgcm0> MXy3NkBp M{DqOIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MlnkNlU4QTB7MEe=
OCI-LY7 M4LtOWNmdGxiVnnhZoltcXS7IFHzd4F6 MYGyMlUuOTVibl2= M{DaeFczKGh? MUTpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M{T3S|I2PzlyOUC3
Farage NYLFPIFDS2WubDDWbYFjcWyrdImgRZN{[Xl? M3K5S|IvPS1zNTDuUS=> NF3WO5g4OiCq Mk\NbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NYP5WJZSOjV5OUC5NFc>
LY7/EBV Ml;HR4VtdCCYaXHibYxqfHliQYPzZZk> MlzlNk42NTF3IH7N M{PCNFczKGh? NEP2VYRqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MlXPNlU4QTB7MEe=
U2932/EBV MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mom0Nk42NTF3IH7N MU[3NkBp NFntWWdqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NX\QXGROOjV5OUC5NFc>
HCT116 NHj0eGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK1MVUxODBibl2= MnL1NlQhcA>? NXPqXoVsTE2VTx?= NFPxW|VqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> Mlr5NlU1QTJ3MUW=
ACH-2 NIHqSmZHfW6ldHnvckBCe3OjeR?= MnG3NU06KG6P MVuyOEBp MYnpcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u NGPqN5gzPTF2OUS2Oy=>
MCF-10A M2fBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyyTolKSzVyPUCuNVfDuTBwMEGgcm0> NInKeJIzPDl3NEi1Oi=>
MCF-7 NIfnUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\DcmlEPTB;MT6xNOKyOC5{MDDuUS=> M3THRVI1QTV2OEW2
SK-BR-3 M1XLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwMEFCtVAvOzVibl2= NW\TUlF{OjR7NUS4OVY>
MDA-MB-231 NFv6[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\vTWM2OD1yLk[4xtExNjF2IH7N MlHpNlQ6PTR6NU[=
PC3 M4XCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHMNZFUUUN3ME2xMlY2yrFyLkO1JI5O MVGyOFk2PDh3Nh?=
HCT116 M4LxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljNTWM2OD1zLkCwxtExNjByIH7N NIXpO3ozPDl3NEi1Oi=>
HCT116-p21-/- M162U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P3OGlEPTB;MT6yOuKyOC5|NzDuUS=> NFLp[IwzPDl3NEi1Oi=>
S1 M37CSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL5VZI4UUN3ME23MlY4yrFyLkK5JI5O NYXvbWNCOjR7NUS4OVY>
SW620 M1K0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7NeVFVUUN3ME2wMlk{yrFyLkK5JI5O NX;heY5uOjR7NUS4OVY>
LOX-IMVI NHPWR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T4V2lEPTB;MD64O:KyOC5yMzDuUS=> NF;Pb4czPDl3NEi1Oi=>
UACC-62 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInWRZhKSzVyPUCuOVbDuTBwMU[gcm0> M1vhNFI1QTV2OEW2
MDA-MB-435 NUfxOWRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O5cmlEPTB;MD65NOKyOC5yNjDuUS=> NEnyc48zPDl3NEi1Oi=>
SF-295 M1zkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r1S2lEPTB;MD64POKyOC5zNTDuUS=> MkHENlQ6PTR6NU[=
A549 M{LnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjXbZVKSzVyPUGuNlbDuTBwMkSgcm0> NGm4NJgzPDl3NEi1Oi=>
H460 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7HUmhKSzVyPUKuOVjDuTBwOECgcm0> MljNNlQ6PTR6NU[=
EKVX NUizfHN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqxcnhlUUN3ME2xMlM{yrFyLkO0JI5O MmDNNlQ6PTR6NU[=
H146 NEi1[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PObmlEPTB;MD6yNuKyOC5yNzDuUS=> MoX1NlQ6PTR6NU[=
H526 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnaXlh2UUN3ME2wMlE2yrFyLkCzJI5O NIi0ZW4zPDl3NEi1Oi=>
HuT-78 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[3W2lEPTB;MT63N:KyOC52NDDuUS=> MX6yOFk2PDh3Nh?=
HA NYSxUYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrrN|gxNjZ{NT2xNI5O NInWe3Q1QCCq MonCbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> M4f3fVI1PzdzNUGw
MS-275 NE\hXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOwMlYzPS1zMH7N MYS0PEBp M1vSeolv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj NYWxdop[OjR5N{G1NVA>
CD4 T NUe5VYhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H4W|Q5KGh? MoPaSWM2OD12LkZCtVEvOCCwTR?= Mk\zNlQ4OjJ2NUS=
CD4 T MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\EZYQ1QCCq NYXBbIdiS0N3ME2xNFfDuTF{NjDuUS=> NGTBWFczPDd{MkS1OC=>
CD4+ T MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LOPWVEPTB;MzDuUS=> NETmZ2UzPDR7NUGwOS=>
A549 NVvlb4w3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX20d2xiOTEkgKOxNFDDqG6P Ml\uNlQwOzZxNEigbC=> NIjOd4hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MlX0NlQ1QDV5OUm=
JJN3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYruZlY5OjRxNEigbC=> M4C1[2VEPTB:MfMAjY5OQyB2OPMAjYg> M4\iUFI1ODNyMUWw
OPM-2 NHjkOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfqUpRbOjRxNEigbC=> NVr1TIZoTUN3MIO9NgKBkW6POzC0PQKBkWh? NXj2VmxtOjRyM{CxOVA>
RPMI-8226 M{TTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOyOE81QCCq M3uwe2VEPTC|PUGuPQKBkW6POzC0PQKBkWh? NFjsW|czPDB|MEG1NC=>
U266 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOyOE81QCCq MVvFR|Uxez1zMPMAjY5OQyB2OPMAjYg> NYHUc|Y3OjRyM{CxOVA>
CA46 M{jVcWFxd3C2b4Ppd{BCe3OjeR?= NEDN[lU3KGh? NYTLNnhlcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= M4n5fFI{QTZ4MU[0
DG75 MlXVRZBweHSxc3nzJGF{e2G7 NVThRnNrPiCq NGq5NmxqdmS3Y3XzJI5wKGGyb4D0c5Nqew>? NHftRXIzOzl4NkG2OC=>
Ramos NEj5bYtCeG:ydH;zbZMhSXO|YYm= M3L5[FYhcA>? NGnSN|VqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> MnrGNlM6PjZzNkS=
ST486 MWfBdI9xfG:|aYOgRZN{[Xl? NEfzdVI3KGh? NEHrdlNqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> M1\We|I{QTZ4MU[0
HuT78 M{nl[WFxd3C2b4Ppd{BCe3OjeR?= NWfBT3VUOS9zMD:xNFAhdk1? MoDxOFghcA>? NFnZTGlqdmS3Y3XzJIFxd3C2b4Ppd{BifCBzIH7N NX7vW|llOjN3M{K3N|I>
DpVp35 M{jjfmFxd3C2b4Ppd{BCe3OjeR?= NH;OOZoyNzFyL{GwNEBvVQ>? NWPrRWhMPDhiaB?= MYXpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NW\MRnBJOjN3M{K3N|I>
DpVp50 MnrFRZBweHSxc3nzJGF{e2G7 MnzwNU8yOC9zMECgcm0> MnPkOFghcA>? MVvpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NVrJUFRbOjN3M{K3N|I>
DpP75  NES1NnBCeG:ydH;zbZMhSXO|YYm= NW\zdpVCOS9zMD:xNFAhdk1? MUW0PEBp MWHpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? Mke4NlM2OzJ5M{K=
SKOV-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nXZVHjiJN{MH7N MVu3NkBp NGW3ZYdFVVOR MVfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MmLRNlMxOTB|NEi=
Brca1 WT NVjHe2lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq5[VVNOeLCk{Kwcm0> MkXoO|IhcA>? NFXhNVZFVVOR M1r6RZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NVXjOHl7OjNyMUCzOFg>
Brca1 Null Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu3b4oy6oDVMkDuUS=> NUTPPI44PzJiaB?= M3fJbGROW09? NFzXRo1z\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NX3CW5NJOjNyMUCzOFg>
OVCAR-8  NITLeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojwNgKBmzJybl2= NYDNR|FGPzJiaB?= MXLEUXNQ M2jKNJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MUiyN|AyODN2OB?=
NCI/ADR-RES MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnQNgKBmzJybl2= MXW3NkBp NHTXdZhFVVOR NXm2bmF{emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? M4XGUlI{ODFyM{S4
HCT116 Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;LRZFQPSCwTT21NEDPxE1? NWPPU2tHOjRiaB?= NX3WZlVpTE2VTx?= MkfVbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NX[4OIw6OjJ7MkS5OVg>
RKO NWO4WJF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[1JI5ONTVyIN88US=> NYrsOWFOOjRiaB?= M4LTdGROW09? M4PxTolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MYSyNlkzPDl3OB?=
CO115 M3;tXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP0OUBvVS13MDFOwG0> MWCyOEBp MXzEUXNQ NYCxSoU6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NEfVOmkzOjl{NEm1PC=>
HFS M3KzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\FOUBvVQ>? MXiyOE81QC95MjDo NYLteI1GcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? Mn\2NlIyODZ{OEK=
LNCaP NGH0PJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f0NlUhdk1? MnL3NlQwPDhxN{KgbC=> NEj3VYhqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MUWyNlExPjJ6Mh?=
A549 M1yzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXqWJM2KG6P M1nLRVI1NzR6L{eyJIg> MlvUbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MVyyNlExPjJ6Mh?=
697  M4W0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzyTWM2OOLCiU5ihKkzNjYEoH7N NIqze2ozOTV|OEKxOi=>
697-R MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjQeFhKSzVy4pEJQgKBkThwNtMgcm3DqA>? MlKxNlE2Ozh{MU[=
HUT78 M{f0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP3TWM2OD1zIH7N NYW0[49jOjFzOUi1OFU>
THJ-16T NILmXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36zWVEhdk1? MVOyOEBp M3i3[YlvcGmkaYTzJINmdGxiZ4Lve5Rp NWrUfpdlOjB6MUC1Olg>
HCT116 MnSxSpVv[3Srb36gRZN{[Xl? Mn\FNlAhdk1? Mnz3PEBp NInqRoVud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS|IH;mJIdmdmW|IHnuJIVqfGincjDkbZJm[3Srb36= MXmyNFc{QTR3NB?=
B104  NHPOS2lHfW6ldHnvckBCe3OjeR?= M2\YXlIhdk1? Mn70NlQwPDhxN{KgbC=> M4DWWIlv[3KnYYPld{B1cGVic4Xy[oFk\SCneIDy[ZN{cW:wIH;mJGNFOjEEoB?= NIHafpQzODZ6NkWwOS=>
HL-60  Moe5R5l1d3SxeHnjbZR6KEG|c3H5 NFfJS2cyNTVyMDDuUS=> M4n2cVI1KGh? M3jWT4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M2\uUVIxPjJ2MU[z
HP100 NWXmU2w{S3m2b4TvfIlkcXS7IFHzd4F6 NWH3OldnOS13MECgcm0> M{DSUlI1KGh? NUTMVIs3cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NWrQV|NrOjB4MkSxOlM>
HL-60  MoX6SpVv[3Srb36gRZN{[Xl? MUmxNEBvVQ>? Mn7GOE83NzF4IHi= Mk[xbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq NU\KV5FZOjB4MkSxOlM>
HP100 MlTiSpVv[3Srb36gRZN{[Xl? NVriN246OTBibl2= NID2UIc1NzZxMU[gbC=> MV\pcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? NGnISGUzODZ{NEG2Ny=>
HL-60  MYrGeY5kfGmxbjDBd5NigQ>? MkLyNVAuPTByIH7N MonrOEBp NUTBWnNx\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg MlnrNlA3OjRzNkO=
HP100 NXTIUoVVTnWwY4Tpc44hSXO|YYm= NIO3VoYyOC13MECgcm0> MoO3OEBp NWXmfFBy\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg NXnmdVN2OjB4MkSxOlM>
11z M{Pz[mtqdmG|ZTDBd5NigQ>? NHTDcVk{NTFyMDDuUS=> M16xbJJm\HWlZYOgTGRCSyCnbor5cYF1cWNiYXP0bZZqfHliKFnDOVDDqD1iNj61JOKyKDBwNjDucY9tN0xr NHTib4gzODZyNUG0OC=>
SKOV-3 NVziUndQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX2c286PC96L{G2JI5O NXvhbY1NPDhiaB?= MoOybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M4rjT|IxPDB2NU[0
OVCAR-3 M1H2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjWe4E1NzhxMU[gcm0> NGHwOnA1QCCq MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NGLtOpYzODRyNEW2OC=>
HBL-2 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[wNk0yOCCwTR?= NIX0dZczPCCq M1H6VWlEPTB;ND6zJI5O NFjTVVczODB4OEC4NC=>
Jeko-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLRepozNTVyIH7N NFH4RYQzPCCq NFLDcIZKSzVyPUGxJI5O MnvlNlAxPjhyOEC=
Granta-519 M1ezZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTFToJIPS12MDDuUS=> M1\Q[|I1KGh? NVjtdnZPUUN3ME21PE42KG6P M2fO[lIxODZ6MEiw
L1236 MUfDfZRwfG:6aXPpeJkhSXO|YYm= M3zvb|Ehdk1vMUCwJO69VQ>? MnTROFghcA>? NGf3OlZGSzVyPUCuNFch|ryP Mki1NVkzOzN2N{C=
L428 MlzrR5l1d3SxeHnjbZR6KEG|c3H5 M{HuV|Ehdk1vMUCwJO69VQ>? MmjhOFghcA>? NWnMfI9nTUN3ME2wMlQ{KM7:TR?= NIHiSpcyQTJ|M{S3NC=>
KM-H2 MUPDfZRwfG:6aXPpeJkhSXO|YYm= NX3XXFlNOSCwTT2xNFAh|ryP MnXyOFghcA>? NF3mTJRGSzVyPUCuOVgh|ryP NXLWW4Z6OTl{M{O0O|A>
L540Cy M1fOSGN6fG:2b4jpZ4l1gSCDc4PhfS=> NXLJfXpxOSCwTT2xNFAh|ryP M3LSV|Q5KGh? M1;hSmVEPTB;MD6xOkDPxE1? NET2NFMyQTJ|M{S3NC=>
G401 MWrGeY5kfGmxbjDBd5NigQ>? MnrGNVAhdk1? MX6yOE81QC95MjDo MULEUXNQ Mm[5bY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MYWxPVIzOTV6Nh?=
STM91-01 MXXGeY5kfGmxbjDBd5NigQ>? MlTWNVAhdk1? MWWyOE81QC95MjDo MnHUSG1UVw>? M4W4fYlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> Mnn2NVkzOjF3OE[=
SJSC  MmTsSpVv[3Srb36gRZN{[Xl? M3XsWVExKG6P NVO3d3lzOjRxNEivO|IhcA>? MYHEUXNQ MWnpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MlTTNVkzOjF3OE[=
BT16  Ml22SpVv[3Srb36gRZN{[Xl? MYqxNEBvVQ>? MmPvNlQwPDhxN{KgbC=> NX3hfJM4TE2VTx?= NHy1dnZqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> M2HUTlE6OjJzNUi2
NCI-H1299 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTRwNtMxNE4zKG6pL33s MoXYNVkyPzl6OUC=
NCI-2882 MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXZTWM2OD1zLkdCtVAvODRibnevcYw> NE\2Z|YyQTF5OUi5NC=>
HCC95 NYTHe2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke2TWM2OD1{LkZCtVAvODVibnevcYw> NInmUG4yQTF5OUi5NC=>
NCI-H23 NULlUlBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW2O5FrUUN3ME2yMlnDuTBwMjDu[{9udA>? MnX5NVkyPzl6OUC=
NCI-H157 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7SeJdKSzVyPUGuOuKyOC5yMjDu[{9udA>? NXvOWlk3OTlzN{m4PVA>
NCI-H460 NF3C[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\ITWM2OD1{LkJCtVAvODdibnevcYw> NGX4fYsyQTF5OUi5NC=>
NCI-H1975 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXHZmlkUUN3ME2xMlPDuTBwMESgcocwdWx? NUnt[op7OTlzN{m4PVA>
NCI-H820 NUWyNY5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHVXJNKSzVyPUKuOOKyOC5zIH7nM41t MXWxPVE4QTh7MB?=
NCI-H1650 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q0bWlEPTB;ND65xtExNjNibnevcYw> NFfiPIQyQTF5OUi5NC=>
DTC1 M3TPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnjNllKSzVyPUCuOVEhdk1? MW[xPFU3PjJ2Nh?=
KAO NV\LUZhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\1NWlEPTB;MD65NUBvVQ>? NYTlVoNPOTh3Nk[yOFY>
SU-CCS-1 NILXXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXqW2FoUUN3ME2wMlg6KG6P MnXsNVg2PjZ{NE[=
SYO-1 NF\LZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwNkegcm0> M4nVR|E5PTZ4MkS2
FUJI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPjTWM2OD1zLkOxJI5O NVnUcm1zOTh3Nk[yOFY>
SKNMC NHLYZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;vTWM2OD1zLkG3JI5O NGfsXYYyQDV4NkK0Oi=>
402-91 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nZbWlEPTB;MT6yOkBvVQ>? NHrxUZEyQDV4NkK0Oi=>
1765-92 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli1TWM2OD1zLke3JI5O NUi1T2l[OTh3Nk[yOFY>
JN-DSRCT-1 MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\MZ5ZsUUN3ME2xMlI2KG6P NUe2fGJsOTh3Nk[yOFY>
NMS-2PC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjkTWM2OD1yLkixJI5O M1jTb|E5PTZ4MkS2
HL60 NUDEVJp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrYTWM2OD1zLki2JI5O MYexPFU3PjJ2Nh?=
A549 Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD2TWM2OD1|LkK0JI5O MlPjNVg2PjZ{NE[=
SW480 M3;0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJwNkmgcm0> NEi0dIYyQDV4NkK0Oi=>
MCF7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7YTWM2OD1|LkW1JI5O M1\lXlE5PTZ4MkS2
PC-3 M4\sbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDO[GNKSzVyPUKuOVEhdk1? MnPpNVg2PjZ{NE[=
MMRU M1W3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnlTWM2OD1{LkW3JI5O NH7WdpQyQDV4NkK0Oi=>
Hs68 M13G[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\wTWM2OD1-MUCgcm0> M2f6clE5PTZ4MkS2
hMSC-001F NF;pXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRT5zMDDuUS=> NXK3dpo{OTh3Nk[yOFY>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: HL60, Jurkat, A549, and MCF-7
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Male scid mice inoculated i.p. with U-937 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~1 mg/kg once or twice a week
  • 投与方法: Treated i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 540.7
化学式

C24H36N4O6S2

CAS No. 128517-07-7
保管
in solvent
別名 FR 901228, NSC 630176

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Romidepsin (FK228, Depsipeptide)を買う | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide)供給者 | Romidepsin (FK228, Depsipeptide)を購入する | Romidepsin (FK228, Depsipeptide)費用 | Romidepsin (FK228, Depsipeptide)生産者 | オーダーRomidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)化学構造 | Romidepsin (FK228, Depsipeptide)分子量 | Romidepsin (FK228, Depsipeptide)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID